Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amlodipine + cilazapril + hydrochlorothiazide is a fixed-dose combination of three antihypertensive agents used for the treatment of high blood pressure (hypertension). Amlodipine is a calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in vasodilation and reduced blood pressure. Cilazapril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, leading to vasodilation and decreased aldosterone-mediated sodium and water retention. Hydrochlorothiazide is a thiazide diuretic that increases renal excretion of sodium and water, further lowering blood pressure. The combination targets multiple mechanisms involved in hypertension for additive or synergistic effects[3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amlodipine + cilazapril + hydrochlorothiazide.